Gillian McGovern, Associate Editor

In addition to oral administration, patients with partial-onset seizures can now take the antiseizure medication via a nasogastric tube if the tablet is crushed and mixed with water.

The antibody drug conjugate was used in combination with the anti-cancer drug SG3249, and demonstrated efficacy in mouse models after 1 week.

Benralizumab was previously approved by the FDA in 2017 as an add-on maintenance therapy for patients 12 years and older.

The results demonstrated similar overall survival between patients with chronic lymphocytic leukemia who discontinued specialized follow-ups versus those who continued.

The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.

Venetoclax, which is approved for leukemia, blocks a function of the BCL-2 protein and has previously shown efficacy in a small proportion of patients with multiple myeloma.

Piezo1 is a protein produced by type 2 innate lymphoid cells when activated by an allergen and can limit the immune cell’s activity when triggered by a reaction.

The treatment is indicated for adolescents at least 12 years of age who weigh at least 25 kg without a previous treatment history of antiretroviral therapies.

Despite the positive results demonstrated in a prior phase 2 trial, AMX0035 failed to meet the phase 3 trial’s primary end point in treating patients with amyotrophic lateral sclerosis.

A study about modifiable risk factors on a “weak spot” in the brain network found that diabetes, pollution, and alcohol were most likely to contribute to dementia disorders.

The decision follows phase 3 trial results that demonstrated improved progression-free survival and confirmed the safety of Dato-DXd in patients with breast cancer.

Positive phase 3 trial results showed that danicopan was more effective than placebo when treating extravascular hemolysis in paroxysmal nocturnal hemoglobinuria.

It is unclear why the vaccines were less effective in women, but researchers note that the findings can be important when determining immune therapy outcomes in patients with melanoma.

The mutations, C594Y and P735R, were found in the GNE gene and may influence sialylation, a process that is crucial for brain development.

Pediatric patients with the variant were approximately 1.44 times more likely develop ALL compared with children who do not have the variant.

The ODD comes after AP303 presented meaningful improvements in renal survival in an ADPKD and the completion of the first study that evaluated healthy human participants.

The manager of clinical pharmacy at UPMC Health Plan describes the significance of the pharmacist’s role in multiple sclerosis care and when collaborating with other health care providers.

The authors note that these findings provide opportunities for health care professionals to utilize social media to reach patients and share accurate information.

The authors believe that pancreatic enzyme therapy has potential in managing patient symptoms, altering the disease course, and the development of standardized care.

The study authors are hopeful that this finding can help in the development of new drugs or treatments for patients with multiple myeloma.

A study that analyzed data from 2000 to 2021 indicated improvements for both leukemia-free survival and overall survival for older patients with acute myeloid leukemia.

Early treatment administration with this regimen also promoted a faster decrease in viral load and shorter viral shedding in patients with hematologic diseases who were positive for COVID-19.

The test scans whole blood samples from individual human donors for the 5 parasite species that can cause malaria in humans and detects Plasmodium RNA and DNA.

The state order was signed on Tuesday and is just a part of an overall mission to strengthen and protect reproductive rights within New York for citizens and those out of state.

The orphan drug designation (ODD) comes after positive results from a phase 2 trial that showed cevidoplenib improved platelet counts by 63.6% and 40.9% in 2 different dose groups.

The indication is for adults and adolescents with moderate to severe immune compromise due to medical conditions or immunosuppressive medications and treatments.

The orphan drug designation (ODD) is a result of positive findings from a phase 2 clinical trial which demonstrated a 100% clinical benefit rate in patients.

The treatment is indicated for patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.

The data comes from 2 phase 4 trials, ENABLE and EMPOWER, which evaluated lanadelumab and the outcomes of treatment in adolescents with hereditary angioedema.

Findings show that magnetic resonance imaging and lumbar puncture are not always needed when managing complications of CAR T-cell therapies, but may be beneficial in certain cases.